mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 401–500 of 1,062
Han, Y., Chen, J., Zou, D., Zheng, P., Li, Q., Wang, H., Li, P., Zhou, X., Zhang, Y., Liu, Y., et al. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s117146 · Cited by 113
“An animal study reported that ketamine might represent the rapid neuroplastic modulator medications, which could lead to the increased synaptic signaling proteins and the increased number of new spine synapses in prefrontal cortex of rats.(50) Hayley and Litteljohn suggested that ketamine could modify the connectivity…”
Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth
Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00065 · Cited by 123
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
“This unique response has been attributed to enhanced neuroplasticity via various downstream effects (Li et al., 2010; Maeng et al., 2008), improved prefrontal glutamate homeostasis (Salvadore et al., 2009), and sustained attenuations in default mode network connectivity and activity (Scheidegger et…”
BackgroundComorbidity Factors and Brain Mechanisms Linking Chronic Stress and Systemic Illness
Duric, V., Clayton, S., Leong, M. L., & Yuan, L.-L. (2016) · Neural Plasticity · doi:10.1155/2016/5460732 · Cited by 98
“Moreover, these rapid actions of ketamine are contingent upon increased BDNF release and activation of mammalian target of rapamycin (mTOR) intracellular pathways, leading to downstream production of synaptic proteins involved in formation of new dendritic spines and synaptogenesis [53, 54].”
BackgroundInflaming sex differences in mood disorders
Rainville, J. R., & Hodes, G. E. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0124-7 · Cited by 123
Jelen, L. A., & Stone, J. M. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2020.1854194 · Cited by 124
“(Li et al., 2010, 2011).”
BackgroundPredictable chronic mild stress in adolescence increases resilience in adulthood
Suo, L., Zhao, L., Si, J., Liu, J., Zhu, W., Chai, B., Zhang, Y., Feng, J., Ding, Z., Luo, Y., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.67 · Cited by 122
“Li et al (2010) reported that the NMDA receptor antagonist ketamine, a fast-acting antidepressant, rapidly activated the mTOR signaling pathway, leading to increased synaptic signaling proteins and an increased number and function of new spine synapses in the PFC in rats.”
BackgroundMethodInfluentialKetamine amplifies induced gamma frequency oscillations in the human cerebral cortex
Shaw, A. D., Saxena, N., E. Jackson, L., Hall, J. E., Singh, K. D., & Muthukumaraswamy, S. D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.012 · Cited by 122
Fischell, J., Van Dyke, A. M., Kvarta, M. D., LeGates, T. A., & Thompson, S. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.112 · Cited by 122
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Ketamine enantiomers in the rapid and sustained antidepressant effects
Muller, J., Pentyala, S., Dilger, J., & Pentyala, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316631267 · Cited by 122
“Furthermore, it is important to note that other antidepressants do not stimulate mTOR [Li et al. 2010].”
BackgroundInfluentialSun, Y., Zhang, H., Wu, Z., Yu, X., Yin, Y., Qian, S., Wang, Z., Huang, J., Wang, W., Liu, T., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00371 · Cited by 126
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Zanos, P., Piantadosi, S. C., Wu, H., Pribut, H. J., Dell, M. J., Can, A., Snodgrass, H. R., Zarate, C. A., Schwarcz, R. M., & Gould, T. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225664 · Cited by 121
“Since a leading hypothesis of ketamine antidepressant action involves the activation of AMPA receptors (Maeng et al., 2008; Li et al., 2010; Autry et al., 2011), we also assessed the role of this receptor in the antidepressant effects of 4-Cl-KYN by pretreatment with the AMPA receptor antagonist…”
BackgroundResultInfluentialDendritic Spine Elimination: Molecular Mechanisms and Implications
Stein, I. S., & Zito, K. (2018) · The Neuroscientist · doi:10.1177/1073858418769644 · Cited by 123
Sanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.224 · Cited by 120
Astrocyte, a Promising Target for Mood Disorder Interventions
Zhou, X., Xiao, Q., Xie, L., Yang, F., Wang, L., & Tu, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00136 · Cited by 120
Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo
Kaddurah-Daouk, R., Bogdanov, M. B., Wikoff, W. R., Zhu, H., Boyle, S. H., Churchill, E., Wang, Z., Rush, A. J., Krishnan, R. R., Pickering, E., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.142 · Cited by 101
“While the exact function of the SLC6A15 SNP is not well understood, from both human and animal studies, it is known that SLC6A15 belongs to the solute carrier 6 (SLC6) gene family, which also Translational Psychiatry includes the transporters for monoamines (including serotonin transporter, the primary target for SSRI…”
BackgroundInfluentialHow does ketamine elicit a rapid antidepressant response?
Kavalali, E. T., & Monteggia, L. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.005 · Cited by 111
“Recent studies have focused on hippocampus and prefrontal cortex as potential sites of action for ketamine [6,7].”
Administration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110
“Not only is ketamine’s complex pharmacology with multiple binding sites in the opioid, dopamine or serotonin systems poorly understood, but also evidence from animal models further demonstrates increased synthesis of brainderived neurotrophic factor and robust activation of mammalian target of rapamycin (mTor) as addi…”
BackgroundmTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics
Zhang, H., Xiao, X., Pan, Z., & Dokudovskaya, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02493-4 · Cited by 123
Navarria, A., Wohleb, E. S., Voleti, B., Ota, K. T., Dutheil, S., Lepack, A. E., Dwyer, J. M., Fuchikami, M., Becker, A., Drago, F., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.012 · Cited by 118
“…the behavioral actions of scopolamine, like ketamine, are blocked by pretreatment with a glutamate AMPA receptor antagonist, consistent with evidence that scopolamine and ketamine cause a rapid, transient burst of glutamate in the mPFC (Li et al., 2010; Moghaddam et al., 1997; Voleti et al., 2013).”
BackgroundSelf-citationYao, N., Skiteva, O., Zhang, X., Svenningsson, P., & Chergui, K. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.239 · Cited by 118
Classics in Chemical Neuroscience: Ketamine
Tyler, M. W., Yourish, H. B., Ionescu, D. F., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00074 · Cited by 106
Leptin in depression: a potential therapeutic target
Ge, T., Fan, J., Yang, W., Cui, R., & Li, B. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1129-1 · Cited by 120
Drug addiction: a curable mental disorder?
Liu, J., & Li, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0180-x · Cited by 120
Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?
Cardamone, L., Salzberg, M., O'Brien, T. J., & Jones, N. C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12052 · Cited by 118
“, 2006), actions that may be linked to the mTOR pathway (Li et al., 2010), a pathway recently been implicated in a broad range of models of epileptogenesis (Wong, 2010).”
BackgroundSalvadore, G., van der Veen, J. W., Zhang, Y., Marenco, S., Machado-Vieira, R., Baumann, J., Ibrahim, L. A., Luckenbaugh, D. A., Shen, J., Drevets, W. C., et al. (2012) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001593 · Cited by 107
“2011) and stimulation of the mammalian target of rapamycin (mTOR) (Li et al. 2010).”
BackgroundDifferential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons
Park, S. W., Lee, J. G., Seo, M. K., Lee, C. H., Cho, H. Y., Lee, B. J., Seol, W., & Kim, Y. H. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000534 · Cited by 111
“Recently, much attention has been directed to mTOR signalling, which is important for dendrite formation and regulation of spine growth (Li et al., 2010a; Okada et al., 2011).”
BackgroundInfluentialSelf-citationPKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine
Xue, W., Wang, W., Gong, T., Zhang, H., Tao, W., Xue, L., Sun, Y., Wang, F., & Chen, G. (2016) · Scientific Reports · doi:10.1038/srep26331 · Cited by 112
Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate
Downey, D., Dutta, A., McKie, S., Dawson, G. R., Dourish, C. T., Craig, K., Smith, M. A., McCarthy, D. J., Harmer, C. J., Goodwin, G. M., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.006 · Cited by 116
“…flow progressively increased throughout the infusion whereas the PET studies measured metabolism at 40 or 120 min post-infusion; by this time, an initial effect on ACC may have worn off, having triggered metabolic cascades that led to later improvement in mood (Autry et al., 2011; Li et al., 2010).”
BackgroundDeyama, S., Bang, E., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.014 · Cited by 116
Self-citationChhibber, A., Woody, S. K., Karim Rumi, M. A., Soares, M. J., & Zhao, L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.05.016 · Cited by 107
“Some studies have implicated the role of ERα (Calabrese et al., 2013) whereas other reports have supported a role for ERβ in mediating this effect (Li et al., 2010; Yang et al., 2014).”
ResultZhou, H., Zhang, Q., Martinez, E., Dale, J., Hu, S., Zhang, E., Liu, K. G., Huang, D., Yang, G., Chen, Z. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06295-x · Cited by 118
Paul, R. K., Singh, N. S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C. E., O’Loughlin, K., Torjman, M. C., Bernier, M., & Wainer, I. W. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000285 · Cited by 115
Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-22.2022 · Cited by 115
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
“While some preclinical studies have reported that ketamine induces antidepressant-like behavioural effects more rapidly than standard antidepressant treatments, conflicting findings have also been reported (Autry et al., 2011; Garcia et al., 2009; Li et al., 2010, 2011).”
BackgroundResultRen, Z., Pribiag, H., Jefferson, S. J., Shorey, M., Fuchs, T., Stellwagen, D., & Luscher, B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.02.009 · Cited by 114
“In contrast to NMDARs, cell surface AMPARs of γ21/2 mice were upregulated by ketamine only in hippocampus and were unaffected in ACC/PLC (however, see below for effects of ketamine at 3 days after treatment; Figure 4C).”
BackgroundInfluentialmTOR complex 1: a key player in neuroadaptations induced by drugs of abuse
Neasta, J., Barak, S., Hamida, S. B., & Ron, D. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12725 · Cited by 114
Koike, H., Iijima, M., & Chaki, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.034 · Cited by 114
“A previous report indicated that ketamine rapidly activates mTOR signaling in the PFC and increases the expression of synaptic proteins, such as PSD-95 and synapsin Iwithin 2 h and synaptogenesis and synaptic activity within 24 h (Li et al., 2010), all of which were prevented by pretreatment with rapamycin; these resu…”
BackgroundMethodInfluentialAleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.007 · Cited by 114
O'Connor, R. M., Grenham, S., Dinan, T. G., & Cryan, J. F. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000448 · Cited by 114
“, 2013) to induce a classic grande mal seizure lasting ∼15 s; (2) acute ketamine treatment (a single dose of 10mg/kg in saline; Li et al., 2010; Autry et al., 2011); (3) chronic (21 d) fluoxetine treatment (10mg/kg/d in saline; Cryan and Lucki, 2000; Cryan et al.”
Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine
Cui, Y., Hu, S., & Hu, H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.002 · Cited by 106
“The disinhibition of the pyramidal neurons then triggers a cascade of changes that alter synaptic communication including potentiated AMPAR signaling [13,16,29,30], stimulated translation and release of brain-derived neurotrophic factor (BDNF) [19,31], and increased mammalian target of rapamycin (mTOR)dependent synapt…”
Sustained Effects of Rapidly Acting Antidepressants Require BDNF-Dependent MeCP2 Phosphorylation
Kim, J.-W., Autry, A. E., Na, E. S., Adachi, M., Björkholm, C., Kavalali, E. T., & Monteggia, L. M. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00868-8 · Cited by 113
Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M. M., & Pariante, C. M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.87 · Cited by 108
Prins, J., Olivier, B., & Korte, S. M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594039 · Cited by 97
“Remarkably, recently it has been demonstrated that the NMDAreceptor antagonist ketamine rapidly activates themammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the PFC of rats [167].”
BackgroundChronic dim light at night provokes reversible depression-like phenotype: possible role for TNF
Bedrosian, T. A., Weil, Z. M., & Nelson, R. J. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.96 · Cited by 112
Lindholm, J., Autio, H., Vesa, L., Antila, H., Lindemann, L., Hoener, M. C., Skolnick, P., Rantamäki, T., & Ċastrén, E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.015 · Cited by 112
“Recent studies have demonstrated that ketamine activates mTOR (mammalian target of rapamycin) mediated signaling pathways in brain, and that these pathways appear to be critical for the antidepressant-like effects of ketamine in rodents (Li et al., 2010).”
BackgroundResultInfluentialFerguson, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.04.005 · Cited by 105
Fluoxetine regulates mTOR signalling in a region-dependent manner in depression-like mice
Liu, X.-L., Luo, L., Mu, R.-H., Liu, B.-B., Geng, D., Liu, Q., & Yi, L.-T. (2015) · Scientific Reports · doi:10.1038/srep16024 · Cited by 103
Exercise increases mTOR signaling in brain regions involved in cognition and emotional behavior
Lloyd, B. A., Hake, H. S., Ishiwata, T., Farmer, C. E., Loetz, E. C., Fleshner, M., Bland, S. T., & Greenwood, B. N. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.01.033 · Cited by 100
“The act that mTOR signaling in the PFC is minimally sensitive to exerise is consistent with prior data suggesting that mechanisms utside of the PFC are involved in the antidepressant effects of xercise [22,98].”
InfluentialAbdallah, C. G., Averill, C. L., Salas, R., Averill, L. A., Baldwin, P. R., Krystal, J. H., Mathew, S. J., & Mathalon, D. H. (2017) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.04.006 · Cited by 111
Mechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
Ghosal, S., Bang, E., Yue, W., Hare, B. D., Lepack, A. E., Girgenti, M. J., & Duman, R. S. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.017 · Cited by 111
Self-citationHermes, G., Li, N., Duman, C., & Duman, R. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.12.019 · Cited by 111
“The prefrontal cortex was dissected per established laboratory protocol [26].”
MethodSelf-citationTeixeira, C. M., Martín, E. D., Sahún, I., Masachs, N., Pujadas, L., Corvelo, A., Bosch, C., Rossi, D., Martinez, A., Maldonado, R., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.153 · Cited by 102
“Given that NR2B is upregulated after stress and NR2B inhibition is sufficient to prevent behavioral deficits induced by stress (Li et al, 2010; Wong et al, 2007), our results suggest that Reelin overexpression increases resilience to stress through NR2B downregulation.”
BackgroundInfluentialDatson, N. A., van den Oever, J. M. E., Korobko, O. B., Magarinos, A. M., de Kloet, E. R., & McEwen, B. S. (2013) · Endocrinology · doi:10.1210/en.2012-2233 · Cited by 105
Brain region–specific action of ketamine as a rapid antidepressant
Chen, M., Ma, S., Liu, H., Dong, Y., Tang, J., Ni, Z., Tan, Y. J., Duan, C.-C., Li, H., Huang, H., et al. (2024) · Science · doi:10.1126/science.ado7010 · Cited by 111
“…s effect have been identified, including brain-derived neurotrophic factor (BDNF) ( 5 , 6 ), AMPAR ( 7 – 9 ), mammalian target of rapamycin (mTOR) ( 10 ), the potassium channel Kcnq2 ( 11 ), the translation initiation factor 4E-binding proteins (4E-BPs) ( 12 ), Menin ( 13 ), and microglia-related…”
Witkin, J. M., Overshiner, C. D., Li, X., Catlow, J. T., Wishart, G. N., Schober, D. A., Heinz, B. A., Nikolayev, A., Tolstikov, V., Anderson, W. H., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216804 · Cited by 110
“There have been advances since 2006 in our understanding of how NMDA receptor blockers might impact the biologic substrates of depression (Li et al., 2010; Autry et al., 2011; Ota and Duman 2013; Pilc et al., 2013).”
BackgroundSelf-citationRoles of glutamate signaling in preclinical and/or mechanistic models of depression
Tokita, K., Yamaji, T., & Hashimoto, K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.016 · Cited by 111
“A recent study demonstrated that not only AMPA signaling but also the mammalian target of rapamycin (mTOR) pathway was involved in the antidepressant actions of ketamine (Li et al., 2010, 2011).”
BackgroundShinohara, R., Taniguchi, M., Ehrlich, A. T., Yokogawa, K., Deguchi, Y., Chérasse, Y., Lazarus, M., Urade, Y., Ogawa, A., Kitaoka, S., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.177 · Cited by 112
Ma, J., Wang, S., Yu, H., Li, D., Luo, S., Zheng, S., Wan, L., & Duan, K. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.03.026 · Cited by 112
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 98
“AMN082 also increased synaptic protein levels (synapsin I, GluR1) and mTOR phosphorylation in the prefrontal cortex [100], which overlaps with ketamine’s known antidepressant mechanisms of action [101].”
DeLorenzo, C., DellaGioia, N., Bloch, M., Sanacora, G., Nabulsi, N., Abdallah, C., Yang, J., Wen, R., Mann, J. J., Krystal, J. H., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.06.024 · Cited by 105
“For example, glutamate release produced by ketamine stimulates alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors, enhancing downstream signaling mechanisms, such as the mammalian target of rapamycin pathway (21).”
Robson, M. J., Elliott, M., Seminerio, M. J., & Matsumoto, R. R. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.002 · Cited by 110
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108
Novel glutamatergic drugs for the treatment of mood disorders
Murrough, J., Lapidus, K., & Soleimani, L. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36689 · Cited by 92
Cui, W., Ning, Y., Hong, W., Wang, J., Liu, Z., & Li, M. D. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1306-3 · Cited by 109
Kang, A., Hao, H., Zheng, X., Liang, Y., Xie, Y., Xie, T., Dai, C., Zhao, Q., Wu, X., Xie, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-100 · Cited by 104
A Word to the Wise About Ketamine
Schatzberg, A. F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101434 · Cited by 109
Stress-Induced Changes of Hippocampal NMDA Receptors: Modulation by Duloxetine Treatment
Calabrese, F., Guidotti, G., Molteni, R., Racagni, G., Mancini, M., & Riva, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037916 · Cited by 107
Fukumoto, K., Iijima, M., & Chaki, S. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3378-0 · Cited by 107
Inhibition of Lactate Transport Erases Drug Memory and Prevents Drug Relapse
Zhang, Y., Xue, Y., Meng, S., Luo, Y., Liang, J., Li, J., Ai, S., Sun, C., Shen, H., Zhu, W., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.007 · Cited by 106
Zanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro · doi:10.1523/eneuro.0285-16.2017 · Cited by 106
“…synapses in the prefrontal cortex, hippocampus, ventral striatum, and other brain regions critically involved in the regulation of mood and reward (Li et al., 2010; Autry et al., 2011; Zanos et al., 2016); synapses that become weakened in response to prodepressive conditions such as chronic…”
BackgroundLiu, J. J., Chiu, Y.-T., DiMattio, K. M., Chen, C., Huang, P., Gentile, T. A., Muschamp, J. W., Cowan, A., Mann, M., & Liu‐Chen, L. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0155-0 · Cited by 106
Deyama, S., Bang, E., Wohleb, E. S., Li, X.-Y., Kato, T., Gerhard, D. M., Dutheil, S., Dwyer, J. M., Taylor, S. R., Picciotto, M. R., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17121368 · Cited by 100
“Previous studies demonstrate that ketamine rapidly increases the number and function of spine synapses on layer V pyramidal neurons in the mPFC through activity-dependent BDNF release and activation of the mechanistic target of rapamycin complex 1 (mTORC1) (5, 20, 23).”
BackgroundSelf-citationDeyama, S., Ishikawa, Y., Yoshikawa, K., Shimoda, K., Ide, S., Satoh, M., & Minami, M. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx023 · Cited by 98
“, 2014) associated depression, to our knowledge, these are the first reported results to suggest that RvD1 and RvD2 act on brain regions, such as the mPFC and DG, to exert antidepressant effects via activation of mTORC1 signaling, similar to rapid-acting antidepressants, such as ketamine and scopolamine (Li et al., 20…”
BackgroundResultNeuronal nitric oxide synthase and affective disorders
Zhou, Q., Zhu, X., Nemes, A. D., & Zhu, D. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.11.004 · Cited by 106
Witkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105
“These morphologic changes are associated with improvement in synaptic function and reduced depression-related behaviors (Li et al., 2010;Dumanet al., 2012;Abdallah et al., 2015;Miller et al., 2016).”
Self-citationZhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
“…an anesthetic with a very fast onset (in hours) and strong antidepressant efficacy (Berman et al. 2000; Zarate et al. 2006), can induce sustained increases in synaptic synapsin I, GluR1, and PSD95 in the rat prefrontal cortex, probably mediated through AMPA and mTOR signaling (Li et al. 2010).”
Liu, R.-J., Duman, C., Kato, T., Hare, B., Lopresto, D., Bang, E., Burgdorf, J., Moskal, J., Taylor, J., Aghajanian, G., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.202 · Cited by 105
Self-citationTSC1/TSC2 signaling in the CNS
Han, J. M., & Sahin, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.02.001 · Cited by 105
“In wild-type neurons, the effect of mTOR activation on spine formation appears to be immediate in induction of synapse associated proteins Arc, synapsin I, PSD95, and GluR1 [71].”
BackgroundDakwar, E., Hart, C. L., Levin, F. R., Nunes, E. V., & Foltin, R. W. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.39 · Cited by 105
Ketamine effects on memory reconsolidation favor a learning model of delusions
Corlett, P. R., Cambridge, V., Gardner, J. M., Piggot, J. S., Turner, D. C., Everitt, J. C., Arana, F. S., Morgan, H. L., Milton, A. L., Lee, J. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065088 · Cited by 105
Lüscher, B., & Möhler, H. (2019) · F1000Research · doi:10.12688/f1000research.18758.1 · Cited by 105
The Ups and Downs of Modelling Mood Disorders in Rodents
Slattery, D. A., & Cryan, J. F. (2014) · ILAR Journal · doi:10.1093/ilar/ilu026 · Cited by 85
Freudenberg, F., Celikel, T., & Reif, A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.005 · Cited by 105
Noppers, I., Niesters, M., Swartjes, M., Bauer, M., Aarts, L., Geleijnse, N., Mooren, R., Dahanl, A., & Sarton, E. (2011) · European Journal of Pain · doi:10.1016/j.ejpain.2011.03.008 · Cited by 95
“All of these effects are thought to arise from a cascade of molecular changes at spinal and supraspinal sites that was initiated by blockade of the NMDAR by ketamine (Chizh, 2007; Christoph et al., 2006; Li et al., 2010; Rabben et al., 1999; Sigtermans et al., 2009a,b; 2010).”
BackgroundPolman, J. A. E., Hunter, R. G., Speksnijder, N., van den Oever, J. M. E., Korobko, O. B., McEwen, B. S., de Kloet, E. R., & Datson, N. A. (2012) · Endocrinology · doi:10.1210/en.2012-1255 · Cited by 102
Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects
Li, S.-X., Han, Y., Xu, L.-Z., Yuan, K., Zhang, R.-X., Sun, C.-Y., Xu, D.-F., Yuan, M., Deng, J.-H., Meng, S.-Q., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.85 · Cited by 98
Estrogen receptor α drives pro-resilient transcription in mouse models of depression
Lorsch, Z. S., Loh, Y.-H. E., Purushothaman, I., Walker, D. M., Parise, E. M., Salery, M., Cahill, M. E., Hodes, G. E., Pfau, M. L., Kronman, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03567-4 · Cited by 104
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
“In part, this is because numerous preclinical studies have implicated neural plasticity in themedial frontal cortex as essential for the antidepressant-like effects of ketamine [14,16].”
BackgroundChou, D., Peng, H.-Y., Lin, T.-B., Lai, C.-Y., Hsieh, M.-C., Wen, Y.-C., Lee, A.-S., Wang, H.-H., Yang, P.-S., Chen, G.-D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.033 · Cited by 104
“, 2016) and mPFC (Li et al., 2010) leading to antidepressant effects, implying that ketamine drives synaptic plasticity, contributing to the antidepressant actions of ketamine.”
MAPK signaling correlates with the antidepressant effects of ketamine
Réus, G. Z., Vieira, F. G., Abelaira, H. M., Michels, M., Tomaz, D. B., dos Santos, M. A. B., Carlessi, A. S., Neotti, M. V., Matias, B. I., da Luz, J. R., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.04.010 · Cited by 104
“In addition to this, ketamine produced a rapid increase in the phosphorylated and activated forms of extracellular ERK1, ERK2 and protein kinase B (PKB/Akt), and the growth factor signaling pathways that have been linked to the activation of mTOR signaling (Li et al., 2010), thus screening the effects of ketamine in M…”
BackgroundTang, J., Yu, W., Chen, S., Gao, Z., & Xiao, B. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2504-0 · Cited by 104
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects
Opal, M. D., Klenotich, S. C., Morais, M., Bessa, J., Winkle, J., Doukas, D., Kay, L. J., Sousa, N., & Dulawa, S. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.144 · Cited by 103
Son, H., Banasr, M., Choi, M., Chae, S. Y., Licznerski, P., Lee, B., Voleti, B., Li, N., Lepack, A., Fournier, N. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201191109 · Cited by 103
“Recent studies demonstrate that atrophy of neuronal processes contributes to the negative effects of stress/depression and can be reversed by certain antidepressants (24, 25).”
BackgroundMethodResultSelf-citationThe promise of ketamine for treatment‐resistant depression: current evidence and future directions
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12646 · Cited by 89
Pilar-Cuéllar, F., Vidal, R., Díaz, A., Castro, E., dos Anjos, S., Pascual-Brazo, J., Linge, R., Vargas, V., Blanco, H., Martínez-Villayandre, B., et al. (2013) · Neural Plasticity · doi:10.1155/2013/537265 · Cited by 90
“The activation of mTOR has been functionally linked with local protein synthesis localized presynaptically as synapsin I, or postsynaptically as PSD-95 and GluR1, and cytoskeletal proteins as the activity-regulated cytoskeletalassociated protein (Arc) [27, 241, 243].”
InfluentialSilote, G. P., Sartim, A. G., Sales, A. J., Eskelund, A., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.04.006 · Cited by 103
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.